• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Psoriasiform Eruption Secondary to PI3K-delta Inhibitor: Expanding the Spectrum of Psoriasiform Paradoxical Reactions?

作者信息

Pesqué David, Sanchez-Gonzalez Blanca, Gallardo Fernando, Segura Sonia, Pujol Ramon M

机构信息

Department of Dermatology, Hospital del Mar - Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB), ES-08003 Barcelona, Spain.

出版信息

Acta Derm Venereol. 2021 Mar 18;101(3):adv00418. doi: 10.2340/00015555-3783.

DOI:10.2340/00015555-3783
PMID:33723614
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9366692/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ff/9366692/e14f9626193d/ActaDV-101-3-969-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ff/9366692/af54e515087e/ActaDV-101-3-969-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ff/9366692/e14f9626193d/ActaDV-101-3-969-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ff/9366692/af54e515087e/ActaDV-101-3-969-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ff/9366692/e14f9626193d/ActaDV-101-3-969-g002.jpg

相似文献

1
Psoriasiform Eruption Secondary to PI3K-delta Inhibitor: Expanding the Spectrum of Psoriasiform Paradoxical Reactions?PI3K-δ抑制剂继发的银屑病样皮疹：银屑病样矛盾反应的范围正在扩大？
Acta Derm Venereol. 2021 Mar 18;101(3):adv00418. doi: 10.2340/00015555-3783.
2
Cisplatin-induced psoriasiform eruption.
Dermatol Ther. 2022 Dec;35(12):e15921. doi: 10.1111/dth.15921. Epub 2022 Oct 17.
3
Psoriasiform drug eruption: A case series with a review of the literature.银屑病样药物疹：病例系列及文献复习。
Exp Dermatol. 2024 Sep;33(9):e15174. doi: 10.1111/exd.15174.
4
A Case of Ixekizumab-induced Psoriasiform Eruption.一例司库奇尤单抗诱发的银屑病样皮疹病例。
Acta Derm Venereol. 2019 Apr 1;99(4):446-447. doi: 10.2340/00015555-3138.
5
Clinical management of paradoxical psoriasiform reactions during TNF- α therapy.肿瘤坏死因子-α治疗期间反常性银屑病样反应的临床管理
Actas Dermosifiliogr. 2014 Oct;105(8):752-61. doi: 10.1016/j.ad.2013.05.007. Epub 2013 Aug 9.
6
Psoriasiform eruption induced by digoxin: confirmed by re-exposure.
J Am Acad Dermatol. 1981 Dec;5(6):702-3. doi: 10.1016/s0190-9622(81)80125-9.
7
Psoriasiform rash following maculopapular eruption during the continued administration of pembrolizumab.在持续使用帕博利珠单抗期间出现斑丘疹后出现银屑病样皮疹。
An Bras Dermatol. 2024 Sep-Oct;99(5):786-788. doi: 10.1016/j.abd.2023.03.012. Epub 2024 Jun 29.
8
Secukinumab-Induced Psoriasiform Eruption.司库奇尤单抗诱导的银屑病样皮疹。
JAMA Dermatol. 2017 Nov 1;153(11):1194-1195. doi: 10.1001/jamadermatol.2017.2826.
9
Case of psoriasiform and pustular eruptions in addition to alopecia as a paradoxical reaction induced by infliximab.除脱发外，出现银屑病样和脓疱性皮疹的病例，作为英夫利昔单抗诱发的矛盾反应。
J Dermatol. 2018 Dec;45(12):e331-e333. doi: 10.1111/1346-8138.14485. Epub 2018 May 31.
10
Mixed lichenoid and psoriasiform drug eruption induced by rifampicin.利福平诱导的混合苔藓样和银屑病样药物疹。
Australas J Dermatol. 2020 May;61(2):e231-e233. doi: 10.1111/ajd.13222. Epub 2019 Dec 15.

引用本文的文献

1
Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis.癌症患者使用磷酸肌醇3-激酶抑制剂作为辅助治疗时皮肤不良事件的发生率：一项系统评价和荟萃分析。
JAMA Oncol. 2022 Oct 13;8(11):1635-43. doi: 10.1001/jamaoncol.2022.4327.
2
Delayed-onset psoriasiform eruption secondary to a phosphoinositide 3-kinase inhibitor: A case report and literature review.磷酸肌醇3-激酶抑制剂继发的迟发性银屑病样皮疹：一例报告及文献复习
JAAD Case Rep. 2022 Apr 1;24:97-100. doi: 10.1016/j.jdcr.2022.02.043. eCollection 2022 Jun.

本文引用的文献

1
Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report.一名难治性滤泡性淋巴瘤患者接受idelalisib单药治疗时出现银屑病样皮疹的管理：病例报告
J Med Case Rep. 2020 Feb 24;14(1):35. doi: 10.1186/s13256-020-2344-9.
2
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.白细胞介素 6 介导淋巴瘤对 PI3K 通路靶向治疗的耐药性。
BMC Cancer. 2019 Oct 10;19(1):936. doi: 10.1186/s12885-019-6057-7.
3
Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition.
继发于磷酸肌醇3激酶抑制的银屑病样皮疹
JAAD Case Rep. 2019 Apr 20;5(5):401-405. doi: 10.1016/j.jdcr.2018.03.005. eCollection 2019 May.
4
Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon.银屑病：经典型与矛盾型。TNF 和 I 型干扰素的阴阳两面。
Front Immunol. 2018 Nov 28;9:2746. doi: 10.3389/fimmu.2018.02746. eCollection 2018.
5
Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer.磷脂酰肌醇3激酶、生长紊乱与癌症
N Engl J Med. 2018 Nov 22;379(21):2052-2062. doi: 10.1056/NEJMra1704560.
6
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.PI3K抑制剂：了解毒性机制与管理
Oncology (Williston Park). 2017 Nov 15;31(11):821-8.
7
First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.西罗莫司（seletalisib）是一种口服生物利用度高的小分子PI3Kδ抑制剂，用于治疗免疫和炎症性疾病的首次人体研究。
Eur J Clin Pharmacol. 2017 May;73(5):581-591. doi: 10.1007/s00228-017-2205-7. Epub 2017 Feb 4.
8
Pharmacological inhibition of PI3K class III enhances the production of pro- and anti-inflammatory cytokines in dendritic cells stimulated by TLR agonists.III类磷脂酰肌醇-3激酶（PI3K）的药理学抑制作用可增强由Toll样受体（TLR）激动剂刺激的树突状细胞中促炎和抗炎细胞因子的产生。
Int Immunopharmacol. 2016 Jul;36:213-217. doi: 10.1016/j.intimp.2016.04.028. Epub 2016 May 8.
9
Phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin pathway in psoriasis pathogenesis. A potential therapeutic target?银屑病发病机制中的磷酸肌醇-3激酶/蛋白激酶B/雷帕霉素哺乳动物靶标通路。一个潜在的治疗靶点？
Acta Derm Venereol. 2014 Jul;94(4):371-9. doi: 10.2340/00015555-1737.